Search Press releases Keywords From To 12 Oct 2023 Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa Read More 9 Oct 2023 UCB to Present New Bimekizumab Data in Hidradenitis Suppurativa, Psoriasis and Psoriatic Arthritis at EADV 2023 Read More 25 Sep 2023 UCB announces approval of RYSTIGGO[®] (rozanolixizumab) and ZILBRYSQ[®] (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in Japan Read More 19 Sep 2023 UCB Provides Update on U.S. Regulatory Review of Bimekizumab Read More 15 Sep 2023 UCB receives CHMP positive opinion of zilucoplan for the treatment of adults with generalized myasthenia gravis in Europe Read More 31 Aug 2023 UCB presents new data at 35th International Epilepsy Congress (IEC) highlighting important advancements across Fintepla[®]▼(fenfluramine) oral solution and broader epilepsies portfolio Read More Pagination First page Previous page Previous … Page 21 Page 22 Page 23 Page 24 Current page 25 Page 26 Page 27 Page 28 Page 29 … Page 25 of 70 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
